Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 166
Filter
1.
Chinese Journal of Preventive Medicine ; (12): 718-727, 2023.
Article in Chinese | WPRIM | ID: wpr-985463

ABSTRACT

Objective: To investigate the clinical characteristics of Aspergillus fumigatus(A.f)-sensitized asthma and allergic bronchopulmonary aspergillosis (ABPA), which provides a foundation for the diagnosis and differential diagnosis of A.f-sensitized asthma and ABPA, as well as the prevention of ABPA. Methods: This was a single-center retrospective case-control study. Collected the clinical data of patients who visited the Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University from December 2018 to May 2022.A total of 122 patients were included, including 64 males (52.5%) and 58 females (47.5%).The age range was 3 to 89 years.The median age was 44 years.The average age was 41.8 years.The patients were divided into three groups (48 ABPA, 35 A.f-sensitized asthma and 39 HDM-sensitized asthma).Analyzed the differences and correlations among clinical indicators in the three groups, and evaluated the risk factors for the development of ABPA in A.f-sensitized asthma.For statistical analysis, metrological data was tested by t-test or Wilcoxon Mann-Whitney. Classification variables by chi-square test or Fisher's exact test. Pearson correlation analysis for normal distribution data.Spearman correlation analysis for skewed distribution data. Influencing factor analysis was performed using multivariate logistic regression analysis. The receiver operating characteristic (ROC) curve was made, the area under the ROC curve (AUC) was calculated, and the sensitivity and specificity of the model were evaluated. Results: Compared with patients with A.f-sensitized asthma, the fractional exhaled nitric oxide (FeNO) [75.00(52.00, 87.00)ppb vs. 40.00(32.00, 52.00)ppb], eosinophils% (EO%) [10.60(6.75, 13.05) vs. 4.10(1.20, 7.30)], eosinophils (EO) [1.50(1.07, 2.20)×109/L vs. 0.33(0.10, 0.54)×109/L], A.f-specific Immunoglobulin E (sIgE) [10.24(4.09, 22.88)KU/L vs. 1.13(0.53, 3.72) KU/L], and sIgE to total IgE(tIgE) ratio (sIgE/tIgE) [0.0049(0.0027, 0.0100) vs. 0.0008(0.0004, 0.0017)] were higher in ABPA patients, the differences were statistically significant (P<0.001). In all patients, tIgE was positively correlated with EO% (r=0.206, P<0.05) and EO (r=0.302, P<0.001). sIgE/tIgE was negatively correlated with one-second rate (FEV1/FVC%) (r=-0.256, P<0.01). The percentage of predicted forced vital capacity [FVC(%)] was negatively correlated with FeNO (r=-0.184, P<0.05).In the ABPA group, the percentage of predicted peak expiratory flow [PEF(%)] was negatively correlated with FeNO (r=-0.295, P<0.05). In the HDM-sensitized asthma group, FeNO was positively correlated with EO% (r=0.49, P<0.01) and EO (r=0.548, P<0.001).The results of logistic regression analysis showed that FeNO and EO were the influencing factors for the development of ABPA in A.f-sensitized asthma. ROC curve analysis results showed that A.f-sIgE (cut-off, 4.108; AUC=0.749;95%CI, 0.632-0.867), sIgE/tIgE(cut-off, 0.0026;AUC=0.749;95%CI, 0.631-0.868), FeNO(cut-off, 55.5;AUC=0.794; 95%CI, 0.687-0.900), EO% (cut-off, 8.70;AUC=0.806;95%CI, 0.709-0.903) and EO (cut-off, 0.815;AUC=0.865;95%CI, 0.779-0.950) had differential diagnostic value in A.f-sensitized asthma and ABPA.The combination of FeNO, EO and EO% had good diagnostic efficiency in differentiating A.f-sensitized asthma from ABPA, with a sensitivity of 91.4% and a specificity of 84.4%. Conclusion: Compared with patients with A.f-sensitized asthma, patients with ABPA have more severe eosinophil inflammation. The higher the FeNO and EO, the more likely A.f-sensitized asthma will develop into ABPA.sIgE/tIgE may have differential diagnostic value in A.f-sensitized asthma and ABPA.The combination of FeNO, EO and EO% has good diagnostic efficacy in differentiating A.f-sensitized asthma from ABPA.


Subject(s)
Male , Female , Humans , Adult , Child, Preschool , Child , Adolescent , Young Adult , Middle Aged , Aged , Aged, 80 and over , Aspergillus fumigatus , Retrospective Studies , Case-Control Studies , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Asthma/diagnosis , Immunoglobulin E , Nitric Oxide
2.
Chinese Medical Journal ; (24): 1949-1958, 2023.
Article in English | WPRIM | ID: wpr-980980

ABSTRACT

BACKGROUND@#Previous research demonstrated that a homozygous mutation of g.136372044G>A (S12N) in caspase recruitment domain family member 9 ( CARD9 ) is critical for producing Aspergillus fumigatus -induced ( Af -induced) T helper 2 (T H 2)-mediated responses in allergic bronchopulmonary aspergillosis (ABPA). However, it remains unclear whether the CARD9S12N mutation, especially the heterozygous occurrence, predisposes the host to ABPA.@*METHODS@#A total of 61 ABPA patients and 264 controls (including 156 healthy controls and 108 asthma patients) were recruited for sequencing the CARD9 locus to clarify whether patients with this heterozygous single-nucleotide polymorphisms are predisposed to the development of ABPA. A series of in vivo and in vitro experiments, such as quantitative real-time polymerase chain reaction, flow cytometry, and RNA isolation and quantification, were used to illuminate the involved mechanism of the disease.@*RESULTS@#The presence of the p.S12N mutation was associated with a significant risk of ABPA in ABPA patients when compared with healthy controls and asthma patients, regardless of Aspergillus sensitivity. Relative to healthy controls without relevant allergies, the mutation of p.S12N was associated with a significant risk of ABPA (OR: 2.69 and 4.17 for GA and AA genotypes, P = 0.003 and 0.029, respectively). Compared with patients with asthma, ABPA patients had a significantly higher heterozygous mutation (GA genotype), indicating that p.S12N might be a significant ABPA-susceptibility locus ( aspergillus sensitized asthma: OR: 3.02, P = 0.009; aspergillus unsensitized asthma: OR: 2.94, P = 0.005). The mutant allele was preferentially expressed in ABPA patients with heterozygous CARD9S12N , which contributes to its functional alterations to facilitate Af -induced T H 2-mediated ABPA development. In terms of mechanism, Card9 wild-type ( Card9WT ) expression levels decreased significantly due to Af -induced decay of its messenger RNA compared to the heterozygous Card9S12N . In addition, ABPA patients with heterozygous CARD9S12N had increased Af -induced interleukin-5 production.@*CONCLUSION@#Our study provides the genetic evidence showing that the heterozygous mutation of CARD9S12N , followed by allele expression imbalance of CARD9S12N , facilitates the development of ABPA.


Subject(s)
Humans , Aspergillosis, Allergic Bronchopulmonary/complications , Aspergillus fumigatus/genetics , Asthma/genetics , Aspergillus , Mutation/genetics , CARD Signaling Adaptor Proteins/genetics
3.
Arq. Asma, Alerg. Imunol ; 6(1): 141-143, jan.mar.2022.
Article in English | LILACS | ID: biblio-1400124

ABSTRACT

Hereditary angioedema (HAE) is a rare autosomal dominant disorder, Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease involving hypersensitivity to the fungi Aspergillus fumigatus which occur in susceptible patient with asthma or cystic fibrosis, also considered a rare disease. We report a case of HAE and ABPA in a single patient. HAE diagnosis was confirmed: C4 = 3 mg/dL, C1INH < 2.8 mg/dL - nephelometry. Former lung function showed elevation RV and RV/FVC, suggesting small airways lung disease. Positive skin prick test to Aspergillus fumigatus (03 mm); total serum IgE level 3,100 IU/mL (nephelometry - BNII Siemens), eosinophilia 11% (528/mm3) and specific A. fumigatus IgG antibodies 6,8 mgA/L (FEIA - fluorenzymeimmunoassay - ThermoFisher) and Chest CT showed mucoid impaction of the bronchi, consistent to current ABPA. Controlling ABPA could prevent and reduce angioedema attacks, and lung structural damage. Early diagnosis and treatment of both diseases should be emphasized to reduce mortality and morbidity


Angioedema hereditário (AEH) é uma doença autossômica dominante; aspergilose broncopulmonar alérgica (ABPA) é uma doença de hipersensibilidade pulmonar relacionada ao esporo de Aspergillus fumigatus, mais suscetível em pacientes com asma e fibrose cística, ambas são consideradas doenças raras. Apresentamos um caso de AEH e ABPA em um paciente. O diagnóstico de AEH foi confirmado com exames laboratoriais: C4 = 3 mg/dL, C1INH < 2,8 mg/dL - nefelometria. Prova de função pulmonar evidenciou aumento de VR e VR/CVF, sugerindo doenças de pequenas vias aéreas. Teste de puntura positivo para A. fumigatus (03 mm); IgE total = 3.100 IU/mL (nefelometria - BNII Siemens), eosinofilia 11% (528/mm3) e IgG específica para A. fumigatus 6,8 mgA/L (FEIA - ThermoFisher), TC de tórax evidenciou impactação mucoide, consistente com ABPA. Controlar ABPA pode prevenir e reduzir as crises de angioedema e os danos ao tecido pulmonar. O diagnóstico precoce de ambas as doenças deve ser enfatizado para reduzir a morbimortalidade.


Subject(s)
Humans , Male , Child , Aspergillosis, Allergic Bronchopulmonary , Angioedemas, Hereditary , Patients , Association , Asthma , Therapeutics , Immunoglobulin E , Rare Diseases , Early Diagnosis , Diagnosis , Eosinophilia
4.
Rev. Asoc. Med. Bahía Blanca ; 32(1): 27-32, 2022.
Article in Spanish | LILACS | ID: biblio-1398510

ABSTRACT

Paciente asmática complicada con Aspergilosis Broncopulmonar Alérgica con bronquiectasias e hiperatenuación mucosa, que persiste con exacerbaciones a repetición y corticodependencia después de dos ciclos de tratamiento con corticoides orales e itraconazol y sin respuesta a la adición de mepolizumab.


Subject(s)
Aspergillosis, Allergic Bronchopulmonary , Case Reports
5.
Rev. cuba. med. mil ; 50(2): e934, 2021. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1341432

ABSTRACT

Introducción: La aspergilosis broncopulmonar alérgica es una enfermedad pulmonar inflamatoria, caracterizada por una reacción de hipersensibilidad a la colonización de la vía aérea por Aspergillus fumigatus en individuos susceptibles, generalmente pacientes con asma y fibrosis quística. Objetivo: Actualizar los conocimientos en el diagnóstico y manejo de la aspergilosis broncopulmonar alérgica. Desarrollo: Se realizó una revisión bibliográfica temática, observacional y retrospectiva, de diciembre de 2019 a julio de 2020. Se accedió a bases de datos como PubMed/MEDLINE, SciElo, ReserchGate, Scopus, ScienceDirect, Redalyc, Latindex, Wed of Science y LILACS, usando los descriptores en Ciencias de la Salud (Aspergillus fumigatus, aspergilosis broncopulmonar alérgica, hipersensibilidad, allergic bronchopulmonary aspergillosis, aspergilose broncopulmonar alérgica, pulmonary aspergillosis, aspergilose pulmonar, hypersensitivity, hipersensibilidade). Se incluyeron artículos escritos en español, inglés o portugués, que informaron sobre la temática relacionada con aspergilosis broncopulmonar alérgica; seleccionados por la lectura del título, el resumen, el texto completo y por la evaluación de las variables (tipos de diseño metodológico, aspectos metodológicos generales propios de cada uno de los diseños encontrados y calidad de la investigación). Con estos criterios, fueron seleccionados 36 artículos nacionales e internacionales que incluyeron artículos originales, revisiones bibliográficas, estudios de intervención, revistas y anuarios estadísticos. Conclusiones: La aspergilosis broncopulmonar alérgica es mucho más frecuente de lo que se suponía, pero con asiduidad se subdiagnostica y el diagnóstico se hace tardíamente, lo que empeora el pronóstico de estos pacientes. Establecer el diagnóstico y tratamiento oportuno ayudará prevenir el desarrollo de serias complicaciones(AU)


Introduction: Allergic bronchopulmonary aspergillosis is an inflammatory lung disease characterized by a hypersensitivity reaction to colonization of the airway by Aspergillus fumigatus in susceptible individuals, generally patients with asthma and cystic fibrosis. Objective: To update knowledge in the diagnosis and management of allergic bronchopulmonary aspergillosis. Development: A thematic, observational and retrospective bibliographic review was carried out, from December / 2019 to July / 2020. Databases such as PubMed / MEDLINE, SciElo, ReserchGate, Scopus, ScienceDirect, Redalyc, Latindex, Wed of Science and LILACS were accessed, using descriptors in Health Sciences (Aspergillus fumigatus, allergic bronchopulmonary aspergillosis, hypersensitivity, allergic bronchopulmonary aspergillosis, allergic bronchopulmonary aspergillose, pulmonary aspergillosis, pulmonary aspergillus, hypersensitivity, hypersensitivity). Articles written in Spanish, English or Portuguese were included, which reported on the subject related to allergic bronchopulmonary aspergillosis, selected by reading the title, the abstract, the full text and by evaluating the variables (types of methodological design, aspects general methodological characteristics of each of the designs found and the quality of the research). With these criteria, 36 national and international articles were selected that included original articles, bibliographic reviews, intervention studies, journals and statistical yearbooks. Conclusions: Allergic bronchopulmonary aspergillosis is much more frequent than previously assumed, but it is frequently underdiagnosed and the diagnosis is made late, which worsens the prognosis of these patients. Establishing timely diagnosis and treatment will help prevent the development of serious complications(AU)


Subject(s)
Humans , Aspergillosis, Allergic Bronchopulmonary , Aspergillus fumigatus , Asthma , Cystic Fibrosis , Lung Diseases , Prognosis , Health Sciences
6.
Neumol. pediátr. (En línea) ; 16(2): 81-84, 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1293292

ABSTRACT

La aspergilosis broncopulmonar alérgica (ABPA) es una reacción de hipersensibilidad secundaria al Aspergillus fumigatus (Af) que complica la evolución en fibrosis quística (FQ). Existen pocos estudios pediátricos de su prevalencia publicados en el mundo y en Chile se desconoce. El objetivo de este trabajo fue estimar la prevalencia de ABPA en niños con FQ en un hospital de referencia, explorar factores de riesgo y describir los criterios diagnósticos, tratamiento y evolución. Se incluyeron retrospectivamente los niños con FQ atendidos en un hospital terciario en Santiago de Chile (Hospital Roberto del Río) entre los años 2011 a 2019, se identificaron aquellos con diagnóstico de ABPA. Se registraron criterios diagnósticos según la Cystic Fibrosis Foundation, presencia de factores de riesgo, tratamientos recibidos y efectos adversos. De 65 pacientes con FQ atendidos en este período, la prevalencia de ABPA fue del 12%. El promedio de edad al diagnóstico fue ± 11 años (5-17 años), predominando la edad adolescente y el género masculino. El 50% cumplieron con los criterios clásicos, el 87,5% usaron antibióticos y el 62,5% corticoides inhalados. La respuesta favorable al tratamiento inicial con corticoides y antifúngico vía oral fue 62,5%, con una exacerbación al momento del estudio. El 25% se comportaron como refractario y el 12,5% respondieron a tratamiento con pulsos de metilprednisolona. El 37,5% presentaron eventos adversos relacionados a corticoides. La prevalencia de ABPA observada es comparable a las series publicadas. Se necesitan trabajos prospectivos para conocer la prevalencia nacional y su tendencia a lo largo de los años, identificando factores de riesgo.


Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity response to Aspergillus fumigatus (Af) and worsens outcome in children with cystic fibrosis (CF). Its prevalence varies in the literature, but we do not know it in Chile. The aim of the study was to know the prevalence of ABPA in children with CF and to describe risk factors, diagnostic criteria, treatment and outcome. We included all patients with CF seen in a tertiary hospital in Santiago, Chile (Hospital Roberto del Río), between 2011 and 2019; ABPA cases (CF Foundation diagnostic criteria) were identified for the estimation of the prevalence. Risk factors, diagnostic criteria and treatment were recorded, as proposed by the Cystic Fibrosis Foundation. A total of 65 patients with CF were identified in the study period, with a prevalence of 12% (8 cases). Mean age at diagnosis ± 11 years (5-17), more frequent in adolescence and male. CF Foundation criteria diagnostic were identified in 50% of cases, with high frequency of antibiotic use (87,5%) and inhaled steroids (62,5%). Positive oral steroids and antifungal treatment response was 62,5%. Refractary response was 25% and 12,5% needed intravenous metilprednisolone pulses. A 37,5% of cases presented adverse effects to steroids. Prevalence of ABPA is comparable to literature. A prospective study is needed to identified national prevalence and trends, identifying risks factors.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Aspergillosis, Allergic Bronchopulmonary/epidemiology , Cystic Fibrosis/epidemiology , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Aspergillosis, Allergic Bronchopulmonary/drug therapy , Aspergillus fumigatus , Chile , Prevalence , Risk Factors , Cystic Fibrosis/complications , Hospitals, Pediatric/statistics & numerical data , Antifungal Agents/therapeutic use
8.
Rev. peru. med. exp. salud publica ; 37(2): 367-370, abr.-jun. 2020. graf
Article in Spanish | LILACS | ID: biblio-1127160

ABSTRACT

RESUMEN El síndrome de asma crítica es la peor consecuencia de una exacerbación aguda de asma. La aspergilosis broncopulmonar alérgica es una de las patologías más frecuentes que se mimetizan con este síndrome y está asociada a un alto riesgo de mortalidad cuando no se realiza el diagnóstico oportuno en pacientes asmáticos de difícil control. Presentamos el caso de un varón de 15 años que ingresó a la unidad de cuidados intensivos con clínica de asma crítica, donde se hizo un diagnóstico de aspergilosis broncopulmonar alérgica y respondió favorablemente con voriconazol y corticoides. En nuestro medio se debe considerar el diagnóstico de aspergilosis broncopulmonar alérgica en todo paciente con clínica de asma crítica o con una enfermedad pulmonar crónica de difícil control; el diagnóstico y el tratamiento oportunos mejoran la calidad de vida y el pronóstico de los pacientes.


ABSTRACT Critical asthma syndrome is the most severe consequence of an acute asthma exacerbation. Allergic bronchopulmonary aspergillosis is one of the most frequent pathologies that mimic critical asthma syndrome and is associated with a high mortality risk when timely diagnosis is not achieved in difficult-to-control asthmatic patients. We present the case of a 15-year-old male who was admitted to the intensive care unit with critical asthma signs and symptoms, where a diagnosis of allergic bronchopulmonary aspergillosis was made. He responded favorably with voriconazole and corticoids. In our context, the diagnosis of allergic bronchopulmonary aspergillosis should be considered in all patients with critical asthma or with a chronic lung disease that is difficult to control. Early diagnosis and treatment improve the quality of life and prognosis of patients.


Subject(s)
Adolescent , Humans , Male , Aspergillosis, Allergic Bronchopulmonary , Asthma , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Asthma/complications , Critical Illness
9.
Neumol. pediátr. (En línea) ; 14(2): 86-91, jul. 2019. ilus, tab
Article in Spanish | LILACS | ID: biblio-1015004

ABSTRACT

Bronchiectasis is a suppurative lung disease with heterogeneous phenotypic characteristics. It is defined as abnormal dilation of the bronchi, losing the existing relationship between bronchial sizes and accompanying artery. According to their form, they can be cylindrical, varicose, saccular or cystic. According to its location, they could be diffuse or localized. The diagnosis of bronchiectasis is usually suspected in patients with chronic cough, mucopurulent bronchorrea, and recurrent respiratory infections. The etiology can be varied, being able to classify in cystic fibrosis bronchiectasis, when there is cystic fibrosis transmembrane regulator (CFTR) gene mutation and not cystic fibrosis, being post infectious the most frequent. Its relationship with childhood is unknown. Severe respiratory infections can predispose in a susceptible subject the so-called theory of the "vicious circle" and the development of these. Persistent bacterial bronchitis in children has been described as a probable cause of not cystic fibrosis bronchiectasis in adults. The treatment is based on the management of symptoms and the prevention of exacerbations. The evidence is poor and many treatments are extrapolated from cystic fibrosis bronchiectasis. We are going to describe the diagnostic and therapeutic approach of non-cystic fibrosis bronchiectasis in adults.


La bronquiectasia es una enfermedad pulmonar supurativa con características fenotípicas heterogéneas. Se define como la dilatación anormal de los bronquios, perdiendo la relación existente entre tamaño bronquial y arteria que acompaña. Según su forma, pueden ser clasificadas en cilíndricas, varicosas, saculares o quísticas y según su etiología presentarse de forma difusa o localizada. El diagnóstico de bronquiectasias se sospecha generalmente en pacientes con tos crónica, broncorrea mucosa, mucupurulenta e infecciones respiratorias recurrentes. La etiología es variada, pudiendo clasificarse en bronquiectasias fibrosis quística, aquellas que se encuentran en el contexto de la mutación del gen regulador transmembrana de fibrosis quística (CFTR) y no fibrosis quística, de etiologías diversas, siendo post infecciosas la gran mayoría. No se conoce con certeza su relación con la infancia, es sabido que infecciones respiratorias severas pueden predisponer en un sujeto susceptible, a la llamada teoría del "circulo vicioso" y el desarrollo de estas. La bronquitis bacteriana persistente en niños se ha descrito como una causa probable del desarrollo de bronquiectasias no fibrosis quística en adultos. El tratamiento se basa en el manejo de los síntomas y la prevención de las exacerbaciones. La evidencia es escasa y la mayoría de las terapias se han investigado en las bronquiectasias tipo fibrosis quística. En este trabajo se explicará el enfrentamiento diagnóstico y terapéutico de los adultos portadores de bronquiectasias no fibrosis quística.


Subject(s)
Humans , Male , Child , Adult , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Aspergillosis, Allergic Bronchopulmonary/therapy , Bronchiectasis/physiopathology , Bronchiectasis/therapy , Cystic Fibrosis/diagnosis , Aspergillosis, Allergic Bronchopulmonary/diagnostic imaging , Bronchiectasis/diagnosis , Bronchiectasis/etiology , Bronchiectasis/epidemiology , Radiography, Thoracic , Macrolides/therapeutic use , Cystic Fibrosis/therapy , Cystic Fibrosis/epidemiology , Anti-Bacterial Agents/therapeutic use
11.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 36(3): 322-328, jul.-set. 2018. tab, graf
Article in Portuguese | LILACS | ID: biblio-977067

ABSTRACT

RESUMO Objetivo: Analisar a associação do exercício físico e da atividade física com a percepção da qualidade do sono em adolescentes. Métodos: Trata-se de um estudo com abordagem quantitativa que integra o levantamento epidemiológico transversal de base escolar e abrangência estadual cuja amostra foi constituída por 6.261 adolescentes (14 a 19 anos), selecionados por meio de uma estratégia de amostragem aleatória de conglomerados. Os dados foram coletados a partir do questionário Global School-based Student Health Survey. O teste do qui-quadrado e a regressão logística binária foram utilizados nas análises dos dados. Resultados: Na amostra, 29% dos adolescentes não faziam exercício e não foram classificados como fisicamente ativos. Os adolescentes que não praticavam exercício físico tinham mais chances de apresentar uma percepção negativa da qualidade do sono (OR 1,13, IC95% 1,04-1,28; p=0,043). Não foi encontrada associação entre o nível de atividade física e a percepção da qualidade do sono (OR 1,01, IC95% 0,89-1,14; p=0,868). Ao serem avaliadas as práticas de forma isolada ou simultânea, constatou-se que aqueles que praticavam exercício físico apresentavam menor chance de terem uma percepção negativa da qualidade do sono (OR 0,82, IC95% 0,71-0,95) e, ao praticarem exercício e, paralelamente, terem uma vida fisicamente ativa, essas chances diminuíam ainda mais (OR 0,79, IC95% 0,68-0,93). Conclusões: Ser classificado como fisicamente ativo, por si só, não foi suficiente para uma melhor percepção da qualidade do sono, pois apenas a prática de exercício físico apresentou tal associação.


ABSTRACT Objective: To analyze the association of exercises and physical activity with the perception of sleep quality by adolescents. Methods: This is a cross-sectional epidemiological survey with statewide coverage, whose sample was composed of 6,261 adolescents (14-19 years old) who were selected by random sampling of conglomerates. The Global School-Based Student Health Survey questionnaire was used for data collection. The chi-square test and the binary logistic regression were applied for data analyses. Results: In the sample, 29% of adolescents did not exercise and were not classified as physically active. Adolescents who did not exercise were more likely to present a negative perception of sleep quality (OR 1.13, 95%CI 1.04-1.28, p=0.043). No association between the level of physical activity and the perception of sleep quality was found (OR 1.01, 95%CI 0.89-1.14, p=0.868). Those who practiced exercises only had less chance of perceiving sleep quality as poor (OR 0.82, 95%CI 0.71-0.95). However, those who practiced exercise and had a physically active life had less chances of having a negative perception of their sleep (OR 0.79, 95%CI 0.68-0.93). Conclusions: Practicing physical activity alone was not enough to increase the chances of positive sleep quality perception. Only physical exercise had a positive association with sleep quality perception.


Subject(s)
Humans , Child , Aspergillosis, Allergic Bronchopulmonary/immunology , Aspergillus fumigatus , Immunoglobulin E , Cystic Fibrosis/complications
13.
Allergy, Asthma & Immunology Research ; : 106-120, 2018.
Article in English | WPRIM | ID: wpr-713205

ABSTRACT

Severe asthma is a heterogeneous disease entity to which diverse cellular components and pathogenetic mechanisms contribute. Current asthma therapies, including new biologic agents, are mainly targeting T helper type 2 cell-dominant inflammation, so that they are often unsatisfactory in the treatment of severe asthma. Respiratory fungal exposure has long been regarded as a precipitating factor for severe asthma phenotype. Moreover, as seen in clinical definitions of allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS), fungal allergy-associated severe asthma phenotype is increasingly thought to have distinct pathobiologic mechanisms requiring different therapeutic approaches other than conventional treatment. However, there are still many unanswered questions on the direct causality of fungal sensitization in inducing severe allergic inflammation in SAFS. Recently, growing evidence suggests that stress response from the largest organelle, endoplasmic reticulum (ER), is closely interconnected to diverse cellular immune/inflammatory platforms, thereby being implicated in severe allergic lung inflammation. Interestingly, a recent study on this issue has suggested that ER stress responses and several associated molecular platforms, including phosphoinositide 3-kinase-δ and mitochondria, may be crucial players in the development of severe allergic inflammation in the SAFS. Defining emerging roles of ER and associated cellular platforms in SAFS may offer promising therapeutic options in the near future.


Subject(s)
Aspergillosis, Allergic Bronchopulmonary , Asthma , Biological Factors , Endoplasmic Reticulum , Fungi , Immunity, Innate , Inflammation , Mitochondria , Organelles , Phenotype , Pneumonia , Precipitating Factors
14.
Asia Pacific Allergy ; (4): e32-2018.
Article in English | WPRIM | ID: wpr-750144
15.
Arq. Asma, Alerg. Imunol ; 1(4): 403-409, out.dez.2017. ilus
Article in Portuguese | LILACS | ID: biblio-1380622

ABSTRACT

Introdução: A bronquiectasia é uma enfermidade caracterizada por dilatações anormais e irreversíveis de um ou mais brônquios. Pode estar associada a diversas outras comorbidades respiratórias, entre elas, a asma. Objetivo: Caracterizar os pacientes asmáticos com bronquiectasias acompanhados em um serviço terciário de alergia. Métodos: Análise retrospectiva de prontuários de pacientes asmáticos que apresentavam bronquiectasias nos exames de tomografia computadorizada de tórax. Os portadores de aspergilose broncopulmonar alérgica (ABPA) foram excluídos. Foram analisados os dados demográficos e exames complementares (espirometria, eosinófilos periféricos, IgE total e IgE específica). A caracterização das bronquiectasias foi avaliada conforme sua localização nos campos pulmonares. Resultados: Quarenta e nove pacientes foram selecionados, sendo 88% do sexo feminino. A média de idade do grupo era de 63 anos, e de tempo de doença de 43 anos. O tratamento prévio de tuberculose (TB), em algum momento da vida, foi relatado por 31% dos pacientes. Doença do refluxo gastroesofágico (DRGE) estava presente em 76% dos pacientes, e a história de tabagismo ativo ou passivo, em 65% dos pacientes. Mais de 80% dos pacientes estavam no step 4 de tratamento da asma, e apresentavam VEF1 reduzido. A média de eosinófilos periféricos foi de 253,4 cel/mm3, de IgE total foi de 458,8 UI/mL, e 69% dos pacientes eram sensibilizados para algum aeroalérgeno. Em relação à localização das bronquiectasias, o lobo superior direito foi o mais acometido, seguido pelo lobo superior esquerdo e lobo inferior direito, respectivamente. Conclusão: Neste estudo, 88% dos pacientes asmáticos com bronquiectasias apresentavam asma grave e função pulmonar alterada, apesar do tratamento otimizado. A bronquiectasia pode estar associada à dificuldade no controle da asma e, embora a história de TB prévia estivesse presente em 31% dos pacientes, a frequência elevada de comprometimento dos lobos superiores (49%) sugere uma frequência maior de doença pulmonar associada à TB.


Introduction: Bronchiectasis is a disease characterized by abnormal and irreversible dilatation of one or more bronchi. It may be associated with several other respiratory comorbidities including asthma. Objective: To characterize asthmatic patients with bronchiectasis seen at a tertiary allergy service. Methods: Retrospective analysis of medical records of asthmatic patients showing bronchiectasis on chest computed tomography scans was conducted. Patients with allergic bronchopulmonary aspergillosis (ABPA) were excluded. Demographic data and complementary tests (spirometry, peripheral eosinophils, total IgE and specific IgE) were analyzed. Bronchiectasis characterization was evaluated according to its location in the lung fields. Results: Forty-nine patients were selected, and 88% were female. Mean age in the group was 63 years, and disease time was 43 years. Previous treatment of tuberculosis (TB) at some point in life was reported by 31% of the patients. Gastroesophageal reflux disease (GERD) was present in 76% of the patients, and history of active or passive smoking in 65%. More than 80% of the patients were on step 4 of asthma treatment and showed reduced FEV1. Mean peripheral eosinophils was 253.4 cell/mm3, total IgE was 458.8 IU/mL, and 69% of the patients were sensitized to some aeroallergen. Regarding the location of bronchiectasis, the right upper lobe was most commonly affected, followed by the left upper lobe and the right lower lobe, respectively. Conclusion: In this study, 88% of asthmatic patients with bronchiectasis had severe asthma and altered pulmonary function despite optimized treatment. Bronchiectasis may be associated with difficulty in controlling asthma. Although previous history of TB was present in 31% of the patients, the high frequency of involvement of the upper lobes (49%) suggests a higher frequency of TB-associated lung disease.


Subject(s)
Humans , Aspergillosis, Allergic Bronchopulmonary , Asthma , Tuberculosis , Bronchiectasis , Patients , Therapeutics , Tobacco Use Disorder , Immunoglobulin E , Gastroesophageal Reflux , Medical Records , Retrospective Studies , Eosinophils , Statistical Data , Hypersensitivity , Lung
16.
Asia Pacific Allergy ; (4): 148-155, 2017.
Article in English | WPRIM | ID: wpr-750108

ABSTRACT

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) in children with asthma, not associated with cystic fibrosis, is yet to receive the recognition it deserves. OBJECTIVE: To highlight the presentation of ABPA in children with asthma. METHODS: This retrospective review documents the occurrence of pediatric ABPA over a period of 31 years in one unit. Children with asthma, eosinophilia and infiltrates on chest radiograph were screened for ABPA. In these patients, demonstration of immediate hypersensitivity response against Aspergillus species along with serological profile and pulmonary function testing were done. Bronchography/computed tomography (CT) of the chest demonstrated central bronchiectasis (CB). CT of the paranasal sinuses was done in patients with upper airways symptoms. In those suspected with allergic Aspergillus sinusitis (AAS) consent was sought from the parents for the invasive procedure needed for the diagnosis of AAS. RESULTS: Of the 349 patients with ABPA diagnosed, 42 (12.03%) were in the pediatric age group. The mean age on presentation was 12.9 ± 4 years with a male preponderance. All patients had asthma and positive intradermal/skin prick test against Aspergillus species. Ring shadows, the most common radiological presentation, were seen in 28 of 42 patients. Bronchography/CT of the chest demonstrated CB, a feature pathognomic of ABPA, in 32 of 42 patients. High attenuation mucus plugs was observed in 7 of 36 patients while ABPA-seropositive was diagnosed in 10 of 42 patients. On imaging, sinusitis was seen in 20 of 30 patients with upper airways symptoms of whom eight had suspected AAS. Three parents consented for surgery, which confirmed the diagnosis. CONCLUSION: This study highlights the need to evaluate asthmatic children for ABPA as also to exclude AAS.


Subject(s)
Child , Humans , Male , Aspergillosis, Allergic Bronchopulmonary , Aspergillus , Asthma , Bronchiectasis , Cystic Fibrosis , Diagnosis , Eosinophilia , Hypersensitivity, Immediate , Mucus , Paranasal Sinuses , Parents , Radiography, Thoracic , Respiratory Function Tests , Retrospective Studies , Sinusitis , Thorax
17.
Asia Pacific Allergy ; (4): 187-191, 2016.
Article in English | WPRIM | ID: wpr-750066

ABSTRACT

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease with small prevalence. Exposure to aspergillus mold causes immunologic hypersensitivity and may cause ranges of symptoms from minimal to detrimental outcomes. Diagnosing and treating the disease before the development of bronchiectasis may save the patient from poor outcomes. This report presents a case of recurrent ABPA without any symptom of asthma, which impeded the correct diagnosis even after numerous hospitalizations.


Subject(s)
Humans , Aspergillosis, Allergic Bronchopulmonary , Aspergillus , Asthma , Bronchiectasis , Delayed Diagnosis , Diagnosis , Fungi , Hospitalization , Hypersensitivity , Lung Diseases , Prevalence
18.
Asia Pacific Allergy ; (4): 67-69, 2016.
Article in English | WPRIM | ID: wpr-750046

ABSTRACT

Allergic bronchopulmonary aspergillosis (ABPA) is infrequently documented in children with asthma. Although collapse is not uncommon, middle lobe syndrome (MLS) as a presentation of ABPA is rather a rarity. A 9-year-old female child with asthma presented with increase in intensity of symptoms along with a right midzone patchy consolidation on a chest radiograph. In addition, an ill-defined opacity abutting the right cardiac border with loss of cardiac silhouette was noted. A right lateral view confirmed a MLS, which was further corroborated by high resolution computed tomography. Central bronchiectasis was also observed, which prompted a work-up for ABPA. The child met 7/8 major diagnostic criteria for ABPA. She was then initiated on oral prednisolone that resulted in a marked clinical improvement within a fortnight. Radiological clearance occurred at 3 months with inflation of the middle lobe. ABPA presenting with MLS in a child is yet to be reported. A high index of suspicion is required to establish the diagnosis of ABPA in a child presenting with MLS. This would obviate the invasive investigations usually done to ascertain the cause of MLS.


Subject(s)
Child , Female , Humans , Aspergillosis, Allergic Bronchopulmonary , Asthma , Bronchiectasis , Diagnosis , Inflation, Economic , Middle Lobe Syndrome , Prednisolone , Radiography, Thoracic
19.
Guatem. pediátr. ; 2(2): 28-31, 2016.
Article in Spanish | LILACS | ID: biblio-981323

ABSTRACT

Aspergillus spp se encuentra ampliamente en el medio ambiente y puede ser aislado tanto de ambientes externos como internos, incluyendo hospitales. la enfermedad pulmonar es causada principalmente por Aspergyllus fumigatus y tiene un gran espectro de síndromes clínicos. La Aspergillosis pulmonar invasiva es una enfermedad severa que se encuentra en pacientes inmunodeprimidos, la Aspergillosis crónica necrotizante es localmente invasiva y se encuentra en pacientes con discreta disminución de la inmunidad o enfermedad pulmonar crónica, el aspergilloma y la enfermedad pulmonar alérgica por aspergillus son formas no invasivas, la última es una manifestación de hipersensibilidad que muy comúnmente afecta a pacientes con asma y fibrosis quística.


Subject(s)
Adult , Aspergillosis, Allergic Bronchopulmonary , Therapeutics
20.
Acta Academiae Medicinae Sinicae ; (6): 611-616, 2016.
Article in English | WPRIM | ID: wpr-277931

ABSTRACT

Allergic bronchopulmonary aspergillosis is one of major pulmonary fungal diseases. Although it is not a rare in clinical settings,the misdiagnosis rate is high and the treatment effectiveness remains unstable. This article reviews the recent advances in the diagnosis and treatment of this disease.


Subject(s)
Humans , Aspergillosis, Allergic Bronchopulmonary , Diagnosis , Therapeutics , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL